Hyaluronic Acid-Based Biomaterials in Tissue Engineering: From Molecular Properties to Re-Generative Applications
Journal of Functional Biomaterials · 14.05.2026 · 17 (5) · 246
DOI: 10.3390/jfb17050246 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Functional Biomaterials, online erschienen am 14.05.2026. Verfasst von Chao-Ming Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung City 40447, Taiwan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Asia University, China Medical University Hospital.
Abstract (Originalsprache)
Hyaluronic acid (HA), a native non-sulfated glycosaminoglycan of the extracellular matrix, has emerged as a central biomaterial in tissue engineering due to its biocompatibility, hydration capacity, and receptor-mediated bioactivity. Beyond its structural role, HA actively regulates cellular behaviors through interactions with receptors such as CD44 and RHAMM, with outcomes highly dependent on molecular weight, degradation state, and matrix context. Recent advances in chemical modification and crosslinking strategies have enabled the development of HA-based hydrogels, nanofibers, and composite systems with tunable mechanics and degradation profiles, supporting applications in bone, cartilage, vascular, and skin regeneration, as well as in emerging platforms such as 3D bioprinting and nanomedicine. However, inconsistent biological responses and limited clinical translation remain key challenges. This review integrates current understanding of HA synthesis, physicochemical properties, degradation, and receptor-mediated signaling, and establishes a mechanistic framework linking molecular characteristics, matrix mechanics, and cell responses. Building on this framework, we outline design strategies for multifunctional HA composites, advanced biofabrication approaches, and receptor-targeted systems, providing a basis for the rational engineering of next-generation HA-based biomaterials with improved translational potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung City 40447, Taiwan.
- Xenotransplantation Translational Research Center, China Medical University Hospital, Taichung City 40447, Taiwan.
- School of Dentistry, China Medical University, Taichung City 40447, Taiwan.
- Department of Bioinformatics and Medical Engineering, Asia University, Taichung City 41354, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung City 40447, Taiwan.
- High Performance Materials Institute for xD Printing, Asia University, Taichung City 41354, Taiwan.
ORCID-Profile: Ming-You Shie, Yi-Wen Chen
Förderung
- National Science and Technology Council
- Asia University
- China Medical University Hospital
- National Science and Technology Council of Taiwan
Zitieren
APA
Su, C. M., Shie, M. Y., Huang, W. N., Chiu, F. J., Chen, H. K., Chen, Y. W., & Shen, Y. F. (2026). Hyaluronic Acid-Based Biomaterials in Tissue Engineering: From Molecular Properties to Re-Generative Applications. Journal of Functional Biomaterials, 17(5), 246. https://doi.org/10.3390/jfb17050246
Vancouver
Su CM, Shie MY, Huang WN, Chiu FJ, Chen HK, Chen YW, et al. Hyaluronic Acid-Based Biomaterials in Tissue Engineering: From Molecular Properties to Re-Generative Applications. Journal of Functional Biomaterials. 2026;17(5):246. doi:10.3390/jfb17050246
BibTeX
@article{Su2026,
author = {Su, Chao-Ming and Shie, Ming-You and Huang, Wan-Ni and Chiu, Fang-Jou and Chen, Hong-Kai and Chen, Yi-Wen and Shen, Yu-Fang},
title = {Hyaluronic Acid-Based Biomaterials in Tissue Engineering: From Molecular Properties to Re-Generative Applications},
journal = {Journal of Functional Biomaterials},
year = {2026},
volume = {17},
number = {5},
pages = {246},
doi = {10.3390/jfb17050246}
}
EUVIMED